COLL
Collegium Pharmaceutical Inc
NASDAQ · Pharmaceuticals
$47.61
+0.69 (+1.47%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 493.78M | 375.13M | 517.48M | 486.77M | 543.10M |
| Net Income | 54.11M | 36.99M | 73.22M | 68.71M | 79.42M |
| EPS | — | — | — | — | — |
| Profit Margin | 11.0% | 10.4% | 14.2% | 14.1% | 14.6% |
| Rev Growth | +31.6% | +31.6% | +4.0% | +18.7% | -0.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 593.25M | 593.25M | 456.72M | 505.83M | 501.20M |
| Total Equity | 159.25M | 159.25M | 1.03B | 1.10B | 1.07B |
| D/E Ratio | 3.73 | 3.73 | 0.44 | 0.46 | 0.47 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 127.01M | 91.67M | 136.97M | 134.63M | 134.48M |
| Free Cash Flow | — | — | 107.99M | 97.48M | 99.20M |